Risk Partners Life Sciences Roundtable 2024, thank you very much! Already for the 26.06.2025 >

Risk Partners at the Financial Lines Forum

13th Hamburg Financial Lines Forum.

On October 12 and 13, the 13th Hamburg Financial Lines Forum took place with the participation of Risk Partners, a traditional event that was once again used this year to discuss current trends.

  • The program began with an overview of current developments and the handling of claims in the Financial Lines, presented by Gabriele Schreiber-Sahin and Michael Hendricks.
  • Dr. Oliver Sieg then shed light on directors' and officers' liability and European legislation in connection with the requirements for cyber security management in companies.
  • The topic of the existence of cardinal obligations in corporate law and their significance for D&O insurance was addressed by Prof. Dr. Jan Lüttringhaus, LL.M. (Columbia), Maître en droit and Prof. Dr. Stefan Korch, LL.M. (Harvard).
  • In the afternoon, Markus Fleck, LL.M., spoke about the challenges of cyber insurance for underwriting,
  • while Prof. Dr. Stefan Kröll discussed the suitability of arbitration proceedings for coverage disputes in excess of loss insurance. 

 

In addition to professional exchange, we were also able to assert the interests of our clients with the insurers on site and, as financial lines specialists, we are already looking forward to the 14th Forum.

Also read our other blog posts

Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
Your question has not been answered?
We will be happy to advise you in a free initial consultation.